Journal September 26, 2026 5 min read

What markers track sleep architecture?

Sleep architecture is tracked by polysomnography-derived markers and emerging molecular and device-based indices. This page surveys the research-use markers under study, from linoleic acid to Syndecan, dexmedetomidine, l

peptides-pro Editorial

Sleep architecture is the structured progression of sleep stages and cycles across a sleep period, conventionally resolved by polysomnography (PSG) into markers such as total sleep time, sleep-stage durations and transitions, sleep-onset and REM latencies, wake after sleep onset, and cycle organization. In research settings, architecture is also tracked by molecular and physiological markers that correlate with or modulate those PSG-derived indices, including blood fatty-acid composition, plasma p-tau217, hypocretin-1, and device-derived sleep-wake signals. No single marker captures architecture; the literature treats PSG as the reference standard and evaluates candidate markers against it.

The work centres on several receptor and signalling families: orexin receptors (OXRs), GLP-1 receptor signalling, adrenergic and serotonergic neurotransmission, and heparan sulfate proteoglycan biology, alongside non-receptor markers such as leptin and linoleic acid.

Research Studies

Linoleic acid and sleep architecture in healthy adults

A registered trial is testing whether cookies high in linoleic acid change sleep quality and sleep architecture, blood fatty-acid composition, and compliance over eight weeks in healthy participants. The stated hypothesis is that eight weeks of consumption will improve sleep quality, increase blood linoleic acid, and achieve greater than 80% compliance [1]. The study is designed to relate a dietary fatty-acid marker to architecture outcomes rather than to establish a mechanism.

Dexmedetomidine and circadian and protein markers in older adults

The DEXTER study is a crossover, double-blind, placebo-controlled pilot evaluating a single sublingual dose of dexmedetomidine in older adults. It is designed to assess safety, feasibility, and biological effects on sleep patterns, 24-hour circadian rhythms, and daily cycles of plasma p-tau217, a neurological protein associated with brain aging [2]. Here the marker set pairs sleep architecture with a circadian and a protein-dynamic readout.

Ayurvedic multi-modality treatment and insomnia

A narrative review examines Ayurvedic approaches to chronic insomnia, including internal adaptogenic herbs, external oil-based therapies, and structured lifestyle regimens. The review frames conventional pharmacotherapy as providing symptomatic relief while raising concerns about dependency, tolerance, and altered sleep architecture, and positions complementary interventions as candidates for evaluation [3]. It is a review, not a controlled trial of a single marker.

Leptin and sleep in an adolescent with anorexia nervosa

A case report describes off-label metreleptin (human recombinant leptin) over 12 days in a 17-year-old female with chronic anorexia nervosa and clinically significant insomnia. Two observation windows were distinguished: day 1 to day 12, and day 12 to two-month follow-up. Over the short-term window, the report notes a modest BMI increase (15.4 to 16.2 kg/m²) and a marked reduction in eating-disorder cognitions [4]. This is a single case and does not establish a marker for architecture in the general population.

Photobiomodulation and sedative-hypnotic reduction

A registered trial evaluates a light-therapy device for reducing sedative-hypnotic use. The background states that long-term sedative-hypnotic use is common in Taiwan despite guidelines recommending short-term use only, and is associated with impaired sleep architecture, cognitive deficits, and elevated dementia risk. The trial positions photobiomodulation as a non-pharmacological alternative intended to avoid the melatonin suppression and timing constraints of bright-light therapy [5].

Remimazolam and postoperative sleep in elderly patients

A randomized controlled trial is testing whether remimazolam is superior to propofol in preserving postoperative sleep quality in elderly patients undergoing laparoscopic radical resection of colorectal cancer. The protocol notes that postoperative sleep disturbance is highly prevalent in this population and that PSG, the gold standard for objective sleep assessment, has not been widely used to evaluate these effects [6]. The comparison is between two anesthetics, with PSG as the architecture marker.

Syndecan reduction and age- and sex-specific sleep in Drosophila

In Drosophila melanogaster, pan-neuronal knockdown of Syndecan (Sdc), a transmembrane heparan sulfate proteoglycan, increased total sleep duration during both day and night in young and aged flies of both sexes, without altering the temporal organization of sleep-wake behaviour under light-dark conditions [7]. This is an animal model; the findings concern a conserved proteoglycan and do not directly translate to human architecture markers.

Radar monitoring in narcolepsy type 1

A prospective study evaluates the clinical feasibility of a millimeter-wave radar sleep monitoring system for diagnosing narcolepsy type 1. The background defines NT1 by cataplexy or reduced cerebrospinal fluid hypocretin-1, and notes that the current gold standard, overnight PSG plus the Multiple Sleep Latency Test, is limited by complex operation, time-consuming procedures, high compliance demands, and poor scalability in primary care [8]. The candidate marker here is a device-derived signal benchmarked against PSG.

Reference-only findings

Additional reports inform the marker landscape without forming the page's core. A review discusses obstructive sleep apnea, GLP-1 receptor agonist pharmacotherapy, and the oral microbiome, describing reproducible oral microbiome dysbiosis in OSA mediated by pathways including intermittent hypoxia-driven immune dysregulation, mouth breathing with salivary desiccation, and elevated salivary glucose [9]. In chronically sleep-deprived mice, neferine, a bisbenzylisoquinoline alkaloid from Nelumbinis plumula, was reported to improve sleep quality by antagonizing orexin receptors in noradrenergic and serotonergic neurons, following in vitro evidence of OXR antagonism [10]. In male mice with comorbid depression and insomnia, lemborexant produced antidepressant- and anxiolytic-like effects with sleep-wake regulation compared with fluoxetine [11]. In male Sprague-Dawley rats exposed to simulated 7000 m hypobaric hypoxia, time-dependent changes were characterized in sleep architecture, HPA axis function, inflammation, and central sleep-regulatory molecules [12].

Comparing marker classes

Marker class	Example	Model or population	What it tracks
Dietary fatty acid	Linoleic acid	Healthy adults	Sleep quality and architecture, blood fatty-acid composition [1]
Protein dynamic	Plasma p-tau217	Older adults	Daily cycles alongside sleep and circadian rhythms [2]
Peptide hormone	Leptin (metreleptin)	Adolescent with anorexia nervosa and insomnia	Sleep and clinical course in a single case [4]
Proteoglycan	Syndecan	Drosophila melanogaster	Total sleep duration and sleep-wake organization [7]
Device signal	Millimeter-wave radar	Narcolepsy type 1	Sleep monitoring benchmarked against PSG [8]

If you are reading this for personal health reasons

The compounds and devices discussed here are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound or device for themselves should speak to a licensed clinician.